x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DIA-0243267
| Product Information | |
|---|---|
| CAS No. | 2656400-84-7 |
| Formula | C29H32ClO5P |
| Molecular Weight | 526.99 |
| SMILES | CC1=C2[C@](C3=CC(C(C)C)=C(C=C3)O)([H])CCC2=CC(OC[P@@]4(O[C@@](C5=CC(Cl)=CC=C5)([H])CCO4)=O)=C1 |
| Target | Others |
| Product Description | THR-β agonist 3 is a potent agonist of THR-β. THR-β agonist 3 has the potential for the research of metabolic diseases such as obesity, hyperlipidemia, hypercholesterolemia, diabetes and other conditions such as steatosis and non-alcoholic steatohepatitis (NASH), atherosclerosis and other related conditions and diseases (extracted from patent WO2021129827A1, compound 6). |
| Format & Storage | |
|---|---|
| Shipping | Room temperature in the continental U.S. Other areas may vary. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
